Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2006 2
2010 4
2011 1
2012 2
2013 2
2014 1
2015 1
2016 1
2019 2
2020 2
2021 2
2022 3
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacokinetics of Ibuprofen in children with cystic fibrosis.
Han EE, Beringer PM, Louie SG, Gill MA, Shapiro BJ. Han EE, et al. Clin Pharmacokinet. 2004;43(3):145-56. doi: 10.2165/00003088-200443030-00001. Clin Pharmacokinet. 2004. PMID: 14871154 Review.
An exaggerated inflammatory response is responsible for the decline of lung function in patients with cystic fibrosis (CF). Ibuprofen is a potent anti-inflammatory agent that demonstrates inhibition of neutrophil activity in vitro at concentrations between 50 …
An exaggerated inflammatory response is responsible for the decline of lung function in patients with cystic fibrosis (CF). …
Factors that predict pursuing sinus surgery in the era of highly effective modulator therapy.
Beswick DM, Han EJ, Mace JC, Markarian K, Alt JA, Bodner TE, Chowdhury NI, Eshaghian PH, Getz AE, Hwang PH, Khanwalkar A, Kimple AJ, Lee JT, Li DA, Norris M, Nayak JV, Owens C, Patel Z, Poch K, Schlosser RJ, Smith KA, Smith TL, Soler ZM, Suh JD, Turner G, Wang MB, Taylor-Cousar JL, Saavedra M. Beswick DM, et al. Int Forum Allergy Rhinol. 2024 Apr;14(4):807-818. doi: 10.1002/alr.23270. Epub 2023 Sep 19. Int Forum Allergy Rhinol. 2024. PMID: 37725072
BACKGROUND: Comorbid chronic rhinosinusitis (CRS) remains unresolved for many people with cystic fibrosis (PwCF). While highly effective modulator therapy improves quality-of-life and symptom severity, the impact of this intervention and other factors associated wit …
BACKGROUND: Comorbid chronic rhinosinusitis (CRS) remains unresolved for many people with cystic fibrosis (PwCF). While highly …
Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis.
Beringer P, Huynh KM, Kriengkauykiat J, Bi L, Hoem N, Louie S, Han E, Nguyen T, Hsu D, Rao PA, Shapiro B, Gill M. Beringer P, et al. Antimicrob Agents Chemother. 2005 Dec;49(12):5013-7. doi: 10.1128/AAC.49.12.5013-5017.2005. Antimicrob Agents Chemother. 2005. PMID: 16304166 Free PMC article. Clinical Trial.
Chronic pulmonary infections with Pseudomonas aeruginosa are the primary cause of morbidity and mortality in patients with cystic fibrosis (CF). The macrolide antibiotics exhibit immunomodulatory and antivirulence activity. ...The purpose of this study was to compar …
Chronic pulmonary infections with Pseudomonas aeruginosa are the primary cause of morbidity and mortality in patients with cystic …
Determining the minimal clinically important difference for the questionnaire of olfactory disorders in people with cystic fibrosis and factors associated with improvement after highly effective modulator therapy.
Miller JE, Taylor-Cousar JL, Overdevest JB, Khatiwada A, Mace JC, Alt JA, Bodner TE, Chowdhury NI, DiMango EA, Eshaghian PH, Getz AE, Gudis DA, Han EJ, Hwang PH, Keating CL, Khanwalkar A, Kimple AJ, Lee JT, Li D, Markarian K, Norris M, Nayak JV, Owens C, Patel ZM, Poch K, Schlosser RJ, Smith KA, Smith TL, Soler ZM, Suh JD, Tervo JP, Turner GA, Wang MB, Saavedra MT, Beswick DM. Miller JE, et al. Int Forum Allergy Rhinol. 2023 Dec 25. doi: 10.1002/alr.23312. Online ahead of print. Int Forum Allergy Rhinol. 2023. PMID: 38145393
INTRODUCTION: Olfactory dysfunction (OD) is common among people with cystic fibrosis (PwCF). The Questionnaire of Olfactory Disorders (QOD) is a validated instrument that evaluates olfactory-specific quality-of-life. ...
INTRODUCTION: Olfactory dysfunction (OD) is common among people with cystic fibrosis (PwCF). The Questionnaire of Olfactory Di …
Inhaled gene therapy of preclinical muco-obstructive lung diseases by nanoparticles capable of breaching the airway mucus barrier.
Kim N, Kwak G, Rodriguez J, Livraghi-Butrico A, Zuo X, Simon V, Han E, Shenoy SK, Pandey N, Mazur M, Birket SE, Kim A, Rowe SM, Boucher R, Hanes J, Suk JS. Kim N, et al. Thorax. 2022 Aug;77(8):812-820. doi: 10.1136/thoraxjnl-2020-215185. Epub 2021 Oct 25. Thorax. 2022. PMID: 34697091 Free PMC article.
METHODS: We investigated the ability of DNA-MPP to mediate reporter and/or therapeutic transgene expression in lung airways of a transgenic mouse model of muco-obstructive lung diseases (ie, Scnn1b-Tg) and in air-liquid interface cultures of primary human bronchial epithelial cel …
METHODS: We investigated the ability of DNA-MPP to mediate reporter and/or therapeutic transgene expression in lung airways of a transgenic …
Vismodegib Identified as a Novel COX-2 Inhibitor via Deep-Learning-Based Drug Repositioning and Molecular Docking Analysis.
Yasir M, Park J, Han ET, Park WS, Han JH, Kwon YS, Lee HJ, Chun W. Yasir M, et al. ACS Omega. 2023 Sep 6;8(37):34160-34170. doi: 10.1021/acsomega.3c05425. eCollection 2023 Sep 19. ACS Omega. 2023. PMID: 37744812 Free PMC article.
To confirm the COX-2 inhibition activity of vismodegib, molecular docking was carried out with the reference compounds of the COX-2 inhibitor, celecoxib, and ibuprofen. Furthermore, the experimental examination of COX-2 inhibition was also carried out using a cell culture …
To confirm the COX-2 inhibition activity of vismodegib, molecular docking was carried out with the reference compounds of the COX-2 inhibito …
Application of elastin-like biopolymer-conjugated C-peptide hydrogel for systemic long-term delivery against diabetic aortic dysfunction.
Lee AJ, Lee YJ, Jeon HY, Kim M, Han ET, Park WS, Hong SH, Kim YM, Ha KS. Lee AJ, et al. Acta Biomater. 2020 Dec;118:32-43. doi: 10.1016/j.actbio.2020.09.055. Epub 2020 Oct 6. Acta Biomater. 2020. PMID: 33035695
Here, we developed K9-C-peptide (human C-peptide conjugated to an elastin-like biopolymer) and investigated its long-term influence on hyperglycemia-induced vascular dysfunction using an aortic endothelium model in diabetic mice. Using pharmacokinetics and in vivo imaging, …
Here, we developed K9-C-peptide (human C-peptide conjugated to an elastin-like biopolymer) and investigated its long-term influence on hyper …
Decreases in Rhinology Care Utilization by People with Cystic Fibrosis on Highly Effective Modulator Therapy.
Han EJ, Beswick DM, Eshaghian PH, Turner GA, Lee JT, Li DA, Wang MB, Taylor-Cousar JL, Suh JD. Han EJ, et al. Ann Otol Rhinol Laryngol. 2024 Mar;133(3):340-344. doi: 10.1177/00034894231211626. Epub 2023 Nov 12. Ann Otol Rhinol Laryngol. 2024. PMID: 37953524
BACKGROUND: Many people with cystic fibrosis (PwCF) have chronic rhinosinusitis (CRS). CRS requires additional management beyond that of pulmonary disease and leads to increased utilization of healthcare resources. ...
BACKGROUND: Many people with cystic fibrosis (PwCF) have chronic rhinosinusitis (CRS). CRS requires additional management beyo …
26 results